

SECURITIES AND EXCHANGE COMMISSION

FORM 8-K

Current report filing

Filing Date: **2024-10-10** | Period of Report: **2024-10-04**

SEC Accession No. [0001193125-24-235949](#)

([HTML Version](#) on [secdatabase.com](#))

FILER

Bellevue Life Sciences Acquisition Corp.

CIK: [1840425](#) | IRS No.: **845052822** | State of Incorporation: **DE** | Fiscal Year End: **1231**

Type: **8-K** | Act: **34** | File No.: [001-41390](#) | Film No.: **241365560**

SIC: **3841** Surgical & medical instruments & apparatus

Mailing Address

10900 NE 4TH STREET,
SUITE 2300
BELLEVUE WA 98004

Business Address

10900 NE 4TH STREET,
SUITE 2300
BELLEVUE WA 98004
425-635-7700

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

FORM 8-K

CURRENT REPORT
Pursuant to Section 13 OR 15(d)
of The Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): October 4, 2024

BELLEVUE LIFE SCIENCES ACQUISITION CORP.

(Exact Name of Registrant as Specified in Charter)

Delaware
(State or Other Jurisdiction
of Incorporation)

001-41390
(Commission
File Number)

84-5052822
(IRS Employer
Identification No.)

10900 NE 4th Street, Suite 2300, Bellevue, WA
(Address of Principal Executive Offices)

98004
(Zip Code)

Registrant's telephone number, including area code (425) 635-7700

Not Applicable
(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- ☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- ☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- ☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class	Trading Symbol(s)	Name of each exchange on which registered
Units, each consisting of one share of common stock, one redeemable warrant and one right	BLACU	The Nasdaq Stock Market LLC
Common stock, par value \$0.0001 per share	BLAC	The Nasdaq Stock Market LLC
Redeemable warrants, exercisable for shares of common stock at an exercise price of \$11.50 per share	BLACW	The Nasdaq Stock Market LLC
Right to receive one-tenth (1/10) of one share of common stock	BLACR	The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 3.01. Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing.

As previously disclosed, on February 15, 2024, the Company received a letter (the “Notice”) from the Listing Qualifications Department of The Nasdaq Stock Market LLC (“Nasdaq”) notifying the Company that the Company no longer meets the minimum 300 public holders requirement for The Nasdaq Capital Market pursuant to Nasdaq Listing Rule 5550(a)(3) (the “Minimum Public Holders Requirement”). On April 1, 2024, the Company submitted to Nasdaq a plan to regain compliance with the Minimum Public Holders Requirement and, on April 17, 2024, the staff of Nasdaq approved the plan and granted the Company an extension until August 13, 2024 to demonstrate compliance with the Minimum Public Holders Requirement (the “Compliance Period”).

On August 20, 2024, the Company received written notice (the “Second Notice”) from Nasdaq stating that the Company has not regained compliance with the Minimum Public Holders Requirement within the Compliance Period. In accordance with the Second Notice, the Company timely requested a hearing before the Hearings Panel (the “Panel”), which automatically stayed any suspension or delisting action of the Company’s securities, and the hearing was held on October 1, 2024. On October 4, 2024, the Panel granted the Company’s request for continued listing on the Nasdaq, subject to the requirement that on or before February 17, 2025, the Company shall demonstrate compliance with Listing Rule 5505, and that during the exception period, the Company shall provide prompt notification of any significant events that occur during this time that may affect the Company’s compliance with Nasdaq requirements.

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Dated: October 10, 2024

BELLEVUE LIFE SCIENCES ACQUISITION CORP.

By: /s/ Kuk Hyoun Hwang

Name: Kuk Hyoun Hwang

Title: Chief Executive Officer

**Document and Entity
Information**

Oct. 04, 2024

Document And Entity Information [Line Items]

<u>Amendment Flag</u>	false
<u>Entity Central Index Key</u>	0001840425
<u>Document Type</u>	8-K
<u>Document Period End Date</u>	Oct. 04, 2024
<u>Entity Registrant Name</u>	BELLEVUE LIFE SCIENCES ACQUISITION CORP.
<u>Entity Incorporation State Country Code</u>	DE
<u>Entity File Number</u>	001-41390
<u>Entity Tax Identification Number</u>	84-5052822
<u>Entity Address, Address Line One</u>	10900 NE 4th Street
<u>Entity Address, Address Line Two</u>	Suite 2300
<u>Entity Address, City or Town</u>	Bellevue
<u>Entity Address, State or Province</u>	WA
<u>Entity Address, Postal Zip Code</u>	98004
<u>City Area Code</u>	(425)
<u>Local Phone Number</u>	635-7700
<u>Written Communications</u>	false
<u>Soliciting Material</u>	false
<u>Pre Commencement Tender Offer</u>	false
<u>Pre Commencement Issuer Tender Offer</u>	false
<u>Entity Emerging Growth Company</u>	true
<u>Entity Ex Transition Period</u>	false
<u>Units Each Consisting Of One Share Of Common Stock One Redeemable Warrant And One Right 2 [Member]</u>	

Document And Entity Information [Line Items]

<u>Security 12b Title</u>	Units, each consisting of one share of common stock, one redeemable warrant and one right
<u>Trading Symbol</u>	BLACU
<u>Security Exchange Name</u>	NASDAQ
<u>Common Stock [Member]</u>	

Document And Entity Information [Line Items]

<u>Security 12b Title</u>	Common stock, par value \$0.0001 per share
<u>Trading Symbol</u>	BLAC
<u>Security Exchange Name</u>	NASDAQ

Redeemable Warrants Exercisable For Shares Of Common
Stock At An Exercise Price Of 11.50 Per Share 1 [Member]

Document And Entity Information [Line Items]

<u>Security 12b Title</u>	Redeemable warrants, exercisable for shares of common stock at an exercise price of \$11.50 per share
<u>Trading Symbol</u>	BLACW

Security Exchange Name

NASDAQ

Right To Receive Onetenth 110 Of One Share Of Common
Stock [Member]

Document And Entity Information [Line Items]

Security 12b Title

Right to receive one-tenth (1/10) of one share of
common stock

Trading Symbol

BLACR

Security Exchange Name

NASDAQ

```

{
  "version": "2.2",
  "instance": {
    "id": "Q84692d8k.htm": {
      "nsPrefix": "blacu",
      "nsURI": "http://BellevueLifeSciencesAcquisitionCorp.com/20241004",
      "dts": {
        "xsi:schema": {
          "local": {
            "blacu-20241004.xsd"
          },
          "remote": [
            "http://www.abrl.org/2003/abrl-instance-2003-12-31.xsd",
            "http://www.abrl.org/2003/abrl-10kbase-2003-12-31.xsd",
            "http://www.abrl.org/2003/xl-2003-12-31.xsd",
            "http://www.abrl.org/2003/xl10k-2003-12-31.xsd",
            "http://www.abrl.org/2005/abridt-2005.xsd",
            "http://www.abrl.org/2006/ref-2006-02-27.xsd",
            "http://www.abrl.org/dtr/type/nonNumeric-2009-12-16.xsd",
            "http://www.abrl.org/dtr/type/numeric-2009-12-16.xsd",
            "https://www.abrl.org/2020/accessible-nomenclatures-2.0.xsd",
            "https://www.abrl.org/dtr/type/2020-01-21/types.xsd",
            "https://www.abrl.org/dtr/type/2022-03-31/types.xsd",
            "https://abrl.fasb.org/act/2023/ata/act-2023.xsd",
            "https://abrl.fasb.org/act/2023/ata/act-2023.xsd",
            "https://abrl.fasb.org/act/2023/ata/act-types-2023.xsd",
            "https://abrl.fasb.org/us-gaap/2023/ata/us-gaap-2023.xsd",
            "https://abrl.fasb.org/us-gaap/2023/ata/us-roles-2023.xsd",
            "https://abrl.fasb.org/us-gaap/2023/ata/us-types-2023.xsd",
            "https://abrl.sec.gov/country/2023/country-2023.xsd",
            "https://abrl.sec.gov/del/2023/del-2023.xsd",
            "https://abrl.sec.gov/naics/2023/naics-2023.xsd"
          ]
        },
        "definitionLink": {
          "local": {
            "blacu-20241004_def.xml"
          }
        },
        "labelLink": {
          "local": {
            "blacu-20241004_lab.xml"
          }
        },
        "presentationLink": {
          "local": {
            "blacu-20241004_pre.xml"
          }
        },
        "inline": {
          "local": {
            "Q84692d8k.htm"
          }
        }
      },
      "keyStandard": 24,
      "keyCustom": 0,
      "axisStandard": 1,
      "axisCustom": 0,
      "memberStandard": 1,
      "memberCustom": 3,
      "hidden": {
        "local": 2,
        "http://abrl.sec.gov/del/2023": 2
      },
      "contextCount": 5,
      "entityCount": 1,
      "segmentCount": 4,
      "elementCount": 33,
      "unitCount": 0,
      "baseTaxonomies": {
        "http://abrl.sec.gov/del/2023": 33
      },
      "report": {
        "xsi": {
          "role": "http://BellevueLifeSciencesAcquisitionCorp.com/20241004/taxonomy/role/DocumentDocumentAndEntityInformation",
          "longName": "100000 - Document - Document and Entity Information",
          "shortName": "Document and Entity Information",
          "isDefault": "true",
          "groupType": "Document",
          "subGroupType": "",
          "ancestor": "Cover",
          "order": "1",
          "firstAnchor": {
            "contextRef": "duration_2024-10-04_to_2024-10-04",
            "name": "del:DocumentType",
            "unitRef": null,
            "xsi:nil": "false",
            "lang": "en-US",
            "decimal": null,
            "ancestors": [
              "p",
              "div",
              "div",
              "body",
              "html"
            ],
            "reportCount": 1,
            "baseRef": "Q84692d8k.htm",
            "first": true,
            "unique": true
          },
          "uniqueAnchor": {
            "contextRef": "duration_2024-10-04_to_2024-10-04",
            "name": "del:DocumentType",
            "unitRef": null,
            "xsi:nil": "false",
            "lang": "en-US",
            "decimal": null,
            "ancestors": [
              "p",
              "div",
              "div",
              "body",
              "html"
            ],
            "reportCount": 1,
            "baseRef": "Q84692d8k.htm",
            "first": true,
            "unique": true
          }
        },
        "tag": {
          "del_AmendmentFlag": {
            "xsi:type": "booleanItemType",
            "nsURI": "http://abrl.sec.gov/del/2023",
            "localName": "AmendmentFlag",
            "presentation": {
              "http://BellevueLifeSciencesAcquisitionCorp.com/20241004/taxonomy/role/DocumentDocumentAndEntityInformation"
            },
            "lang": {
              "xsi": {
                "role": {
                  "label": "Amendment Flag",
                  "targetLabel": "Amendment Flag",
                  "documentation": "Boolean Flag that is true when the XBRL content amends previously-filed or accepted submission."
                }
              }
            },
            "auth_ref": []
          },
          "del_CityAreaCode": {
            "xsi:type": "normalizedStringItemType",
            "nsURI": "http://abrl.sec.gov/del/2023",
            "localName": "CityAreaCode",
            "presentation": {
              "http://BellevueLifeSciencesAcquisitionCorp.com/20241004/taxonomy/role/DocumentDocumentAndEntityInformation"
            },
            "lang": {
              "xsi": {
                "role": {
                  "label": "City Area Code",
                  "targetLabel": "City Area Code",
                  "documentation": "Area code of city"
                }
              }
            },
            "auth_ref": []
          },
          "us-gaap_ClassOfStockDomain": {
            "xsi:type": "domainItemType",
            "nsURI": "http://fasb.org/us-gaap/2023",
            "localName": "ClassOfStockDomain",
            "presentation": {
              "http://BellevueLifeSciencesAcquisitionCorp.com/20241004/taxonomy/role/DocumentDocumentAndEntityInformation"
            },
            "lang": {
              "xsi": {
                "role": {
                  "label": "Class of Stock [Domain]",
                  "targetLabel": "Class of Stock [Domain]"
                }
              }
            },
            "auth_ref": []
          },
          "us-gaap_CommonStockMember": {
            "xsi:type": "domainItemType",
            "nsURI": "http://fasb.org/us-gaap/2023",
            "localName": "CommonStockMember",
            "presentation": {
              "http://BellevueLifeSciencesAcquisitionCorp.com/20241004/taxonomy/role/DocumentDocumentAndEntityInformation"
            },
            "lang": {
              "xsi": {
                "role": {
                  "label": "Common Stock [Member]",
                  "targetLabel": "Common Stock [Member]"
                }
              }
            },
            "auth_ref": []
          },
          "del_CoverAbstract": {
            "xsi:type": "stringItemType",
            "nsURI": "http://abrl.sec.gov/del/2023",
            "localName": "CoverAbstract",
            "lang": {
              "xsi": {
                "role": {
                  "label": "Cover [Abstract]",
                  "targetLabel": "Cover [Abstract]"
                }
              }
            }
          }
        }
      }
    }
  }
}

```



```

    "documentation": "Cover page."
  },
  {
    "auth_ref": []
  },
  {
    "docu DocumentAndEntityInformationLineItems": {
      "abbrType": "stringItemType",
      "nsuri": "http://bellevueLifeSciencesAcquisitionCorp.com/20241004",
      "localname": "DocumentAndEntityInformationLineItems",
      "presentation": {
        "http://bellevueLifeSciencesAcquisitionCorp.com/20241004/taxonomy/role/DocumentDocumentAndEntityInformation"
      },
      "lang": {
        "en-us": {
          "role": {
            "label": "Document And Entity Information [Line Items]",
            "terseLabel": "Document And Entity Information [Line Items]"
          }
        }
      },
      "auth_ref": []
    },
    "docu DocumentAndEntityInformationTable": {
      "abbrType": "stringItemType",
      "nsuri": "http://bellevueLifeSciencesAcquisitionCorp.com/20241004",
      "localname": "DocumentAndEntityInformationTable",
      "presentation": {
        "http://bellevueLifeSciencesAcquisitionCorp.com/20241004/taxonomy/role/DocumentDocumentAndEntityInformation"
      },
      "lang": {
        "en-us": {
          "role": {
            "label": "Document And Entity Information [Table]",
            "terseLabel": "Document And Entity Information [Table]"
          }
        }
      },
      "auth_ref": []
    },
    "dei DocumentPeriodEndDate": {
      "abbrType": "dateTimeType",
      "nsuri": "http://xbrl.sec.gov/dai/2023",
      "localname": "DocumentPeriodEndDate",
      "presentation": {
        "http://bellevueLifeSciencesAcquisitionCorp.com/20241004/taxonomy/role/DocumentDocumentAndEntityInformation"
      },
      "lang": {
        "en-us": {
          "role": {
            "label": "Document Period End Date",
            "documentation": "For the EDGAR submission types of Form N-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-K: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD."
          }
        }
      },
      "auth_ref": []
    },
    "dei DocumentType": {
      "abbrType": "submissionTypeItem",
      "nsuri": "http://xbrl.sec.gov/dai/2023",
      "localname": "DocumentType",
      "presentation": {
        "http://bellevueLifeSciencesAcquisitionCorp.com/20241004/taxonomy/role/DocumentDocumentAndEntityInformation"
      },
      "lang": {
        "en-us": {
          "role": {
            "label": "Document Type",
            "terseLabel": "Document Type",
            "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'."
          }
        }
      },
      "auth_ref": []
    },
    "dei EntityAddressAddressLine1": {
      "abbrType": "normalizedStringItemType",
      "nsuri": "http://xbrl.sec.gov/dai/2023",
      "localname": "EntityAddressAddressLine1",
      "presentation": {
        "http://bellevueLifeSciencesAcquisitionCorp.com/20241004/taxonomy/role/DocumentDocumentAndEntityInformation"
      },
      "lang": {
        "en-us": {
          "role": {
            "label": "Entity Address, Address Line One",
            "terseLabel": "Entity Address, Address Line One",
            "documentation": "Address Line 1 such as Attr, Building Name, Street Name"
          }
        }
      },
      "auth_ref": []
    },
    "dei EntityAddressAddressLine2": {
      "abbrType": "normalizedStringItemType",
      "nsuri": "http://xbrl.sec.gov/dai/2023",
      "localname": "EntityAddressAddressLine2",
      "presentation": {
        "http://bellevueLifeSciencesAcquisitionCorp.com/20241004/taxonomy/role/DocumentDocumentAndEntityInformation"
      },
      "lang": {
        "en-us": {
          "role": {
            "label": "Entity Address, Address Line Two",
            "terseLabel": "Entity Address, Address Line Two",
            "documentation": "Address Line 2 such as Street or Suite number"
          }
        }
      },
      "auth_ref": []
    },
    "dei EntityAddressCityOrTown": {
      "abbrType": "normalizedStringItemType",
      "nsuri": "http://xbrl.sec.gov/dai/2023",
      "localname": "EntityAddressCityOrTown",
      "presentation": {
        "http://bellevueLifeSciencesAcquisitionCorp.com/20241004/taxonomy/role/DocumentDocumentAndEntityInformation"
      },
      "lang": {
        "en-us": {
          "role": {
            "label": "Entity Address, City or Town",
            "terseLabel": "Entity Address, City or Town",
            "documentation": "Name of the City or Town"
          }
        }
      },
      "auth_ref": []
    },
    "dei EntityAddressPostalZipCode": {
      "abbrType": "normalizedStringItemType",
      "nsuri": "http://xbrl.sec.gov/dai/2023",
      "localname": "EntityAddressPostalZipCode",
      "presentation": {
        "http://bellevueLifeSciencesAcquisitionCorp.com/20241004/taxonomy/role/DocumentDocumentAndEntityInformation"
      },
      "lang": {
        "en-us": {
          "role": {
            "label": "Entity Address, Postal Zip Code",
            "terseLabel": "Entity Address, Postal Zip Code",
            "documentation": "Code for the postal or zip code"
          }
        }
      },
      "auth_ref": []
    },
    "dei EntityAddressStateOrProvince": {
      "abbrType": "stateOrProvincialType",
      "nsuri": "http://xbrl.sec.gov/dai/2023",
      "localname": "EntityAddressStateOrProvince",
      "presentation": {
        "http://bellevueLifeSciencesAcquisitionCorp.com/20241004/taxonomy/role/DocumentDocumentAndEntityInformation"
      },
      "lang": {
        "en-us": {
          "role": {
            "label": "Entity Address, State or Province",
            "terseLabel": "Entity Address, State or Province",
            "documentation": "Name of the state or province."
          }
        }
      },
      "auth_ref": []
    },
    "dei EntityCentralIndexKey": {
      "abbrType": "centralIndexKeyItemType",
      "nsuri": "http://xbrl.sec.gov/dai/2023",
      "localname": "EntityCentralIndexKey",
      "presentation": {
        "http://bellevueLifeSciencesAcquisitionCorp.com/20241004/taxonomy/role/DocumentDocumentAndEntityInformation"
      },
      "lang": {
        "en-us": {
          "role": {
            "label": "Entity Central Index Key",
            "terseLabel": "Entity Central Index Key",
            "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK."
          }
        }
      },
      "auth_ref": {
        "pi"
      }
    },
    "dei EntityEmergingGrowthCompany": {
      "abbrType": "booleanItemType",
      "nsuri": "http://xbrl.sec.gov/dai/2023",
      "localname": "EntityEmergingGrowthCompany",
      "presentation": {
        "http://bellevueLifeSciencesAcquisitionCorp.com/20241004/taxonomy/role/DocumentDocumentAndEntityInformation"
      },
      "lang": {
        "en-us": {
          "role": {
            "label": "Entity Emerging Growth Company",
            "terseLabel": "Entity Emerging Growth Company",
            "documentation": "Indicate if registrant meets the emerging growth company criteria."
          }
        }
      },
      "auth_ref": {
        "pi"
      }
    }
  }

```

```

},
"dei_EntityExTransitionPeriod": {
  "shortType": "booleanItemType",
  "nsuri": "http://xbrl.sec.gov/di/2023",
  "localName": "EntityExTransitionPeriod",
  "presentation": {
    "http://BellevueLifeSciencesAcquisitionCorp.com/20241004/taxonomy/role/DocumentDocumentAndEntityInformation"
  },
  "lang": {
    "en-us": {
      "role": {
        "label": "Entity Ex Transition Period",
        "xbrlLabel": "Entity Ex Transition Period",
        "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards."
      }
    }
  },
  "auth_ref": {
    "x3"
  },
  "auth_ref": []
},
"dei_EntityFileNumber": {
  "shortType": "fileNumberItemType",
  "nsuri": "http://xbrl.sec.gov/di/2023",
  "localName": "EntityFileNumber",
  "presentation": {
    "http://BellevueLifeSciencesAcquisitionCorp.com/20241004/taxonomy/role/DocumentDocumentAndEntityInformation"
  },
  "lang": {
    "en-us": {
      "role": {
        "label": "Entity File Number",
        "xbrlLabel": "Entity File Number",
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen."
      }
    }
  },
  "auth_ref": {
    "x3"
  },
  "auth_ref": []
},
"dei_EntityIncorporationStateCountryCode": {
  "shortType": "majorStateCountryItemType",
  "nsuri": "http://xbrl.sec.gov/di/2023",
  "localName": "EntityIncorporationStateCountryCode",
  "presentation": {
    "http://BellevueLifeSciencesAcquisitionCorp.com/20241004/taxonomy/role/DocumentDocumentAndEntityInformation"
  },
  "lang": {
    "en-us": {
      "role": {
        "label": "Entity Incorporation State Country Code",
        "xbrlLabel": "Entity Incorporation State Country Code",
        "documentation": "Two-character EDGAR code representing the state or country of incorporation."
      }
    }
  },
  "auth_ref": {
    "x3"
  },
  "auth_ref": []
},
"dei_EntityRegistrantName": {
  "shortType": "normalizedStringItemType",
  "nsuri": "http://xbrl.sec.gov/di/2023",
  "localName": "EntityRegistrantName",
  "presentation": {
    "http://BellevueLifeSciencesAcquisitionCorp.com/20241004/taxonomy/role/DocumentDocumentAndEntityInformation"
  },
  "lang": {
    "en-us": {
      "role": {
        "label": "Entity Registrant Name",
        "xbrlLabel": "Entity Registrant Name",
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC."
      }
    }
  },
  "auth_ref": {
    "x3"
  },
  "auth_ref": []
},
"dei_EntityTaxIdentificationNumber": {
  "shortType": "employerIdItemType",
  "nsuri": "http://xbrl.sec.gov/di/2023",
  "localName": "EntityTaxIdentificationNumber",
  "presentation": {
    "http://BellevueLifeSciencesAcquisitionCorp.com/20241004/taxonomy/role/DocumentDocumentAndEntityInformation"
  },
  "lang": {
    "en-us": {
      "role": {
        "label": "Entity Tax Identification Number",
        "xbrlLabel": "Entity Tax Identification Number",
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS."
      }
    }
  },
  "auth_ref": {
    "x3"
  },
  "auth_ref": []
},
"dei_LocalPhoneNumber": {
  "shortType": "normalizedStringItemType",
  "nsuri": "http://xbrl.sec.gov/di/2023",
  "localName": "LocalPhoneNumber",
  "presentation": {
    "http://BellevueLifeSciencesAcquisitionCorp.com/20241004/taxonomy/role/DocumentDocumentAndEntityInformation"
  },
  "lang": {
    "en-us": {
      "role": {
        "label": "Local Phone Number",
        "xbrlLabel": "Local Phone Number",
        "documentation": "Local phone number for entity."
      }
    }
  },
  "auth_ref": {
    "x3"
  },
  "auth_ref": []
},
"dei_PreCommencementIssuerTenderOffer": {
  "shortType": "booleanItemType",
  "nsuri": "http://xbrl.sec.gov/di/2023",
  "localName": "PreCommencementIssuerTenderOffer",
  "presentation": {
    "http://BellevueLifeSciencesAcquisitionCorp.com/20241004/taxonomy/role/DocumentDocumentAndEntityInformation"
  },
  "lang": {
    "en-us": {
      "role": {
        "label": "Pre Commencement Issuer Tender Offer",
        "xbrlLabel": "Pre Commencement Issuer Tender Offer",
        "documentation": "Boolean flag that is true when the Form S-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13a-4(c) under the Exchange Act."
      }
    }
  },
  "auth_ref": {
    "x3"
  },
  "auth_ref": []
},
"dei_PreCommencementTenderOffer": {
  "shortType": "booleanItemType",
  "nsuri": "http://xbrl.sec.gov/di/2023",
  "localName": "PreCommencementTenderOffer",
  "presentation": {
    "http://BellevueLifeSciencesAcquisitionCorp.com/20241004/taxonomy/role/DocumentDocumentAndEntityInformation"
  },
  "lang": {
    "en-us": {
      "role": {
        "label": "Pre Commencement Tender Offer",
        "xbrlLabel": "Pre Commencement Tender Offer",
        "documentation": "Boolean flag that is true when the Form S-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act."
      }
    }
  },
  "auth_ref": {
    "x4"
  },
  "auth_ref": []
},
"blacu_RedeemableWarrantsExercisableForSharesOfCommonStockAtAnExercisePriceOf11.50PerShare1Member": {
  "shortType": "domainItemType",
  "nsuri": "http://BellevueLifeSciencesAcquisitionCorp.com/20241004",
  "localName": "RedeemableWarrantsExercisableForSharesOfCommonStockAtAnExercisePriceOf11.50PerShare1Member",
  "presentation": {
    "http://BellevueLifeSciencesAcquisitionCorp.com/20241004/taxonomy/role/DocumentDocumentAndEntityInformation"
  },
  "lang": {
    "en-us": {
      "role": {
        "label": "Redeemable Warrants Exercisable For Shares Of Common Stock At An Exercise Price Of 11.50 Per Share 1 [Member]",
        "xbrlLabel": "Redeemable Warrants Exercisable For Shares Of Common Stock At An Exercise Price Of 11.50 Per Share 1 [Member]"
      }
    }
  },
  "auth_ref": {
    "x3"
  },
  "auth_ref": []
},
"blacu_RightToReceiveOnetenth100OfOneShareOfCommonStockMember": {
  "shortType": "domainItemType",
  "nsuri": "http://xbrl.sec.gov/di/2023",
  "localName": "RightToReceiveOnetenth100OfOneShareOfCommonStockMember",
  "presentation": {
    "http://BellevueLifeSciencesAcquisitionCorp.com/20241004/taxonomy/role/DocumentDocumentAndEntityInformation"
  },
  "lang": {
    "en-us": {
      "role": {
        "label": "Right To Receive Onetenth 110 Of One Share Of Common Stock [Member]",
        "xbrlLabel": "Right To Receive Onetenth 110 Of One Share Of Common Stock [Member]"
      }
    }
  },
  "auth_ref": {
    "x3"
  },
  "auth_ref": []
},
"dei_Security12bTitle": {
  "shortType": "securityTitleItemType",
  "nsuri": "http://xbrl.sec.gov/di/2023",
  "localName": "Security12bTitle",
  "presentation": {
    "http://BellevueLifeSciencesAcquisitionCorp.com/20241004/taxonomy/role/DocumentDocumentAndEntityInformation"
  },
  "lang": {
    "en-us": {
      "role": {
        "label": "Security 12b Title",
        "xbrlLabel": "Security 12b Title",
        "documentation": "Title of a 12(b) registered security."
      }
    }
  },
  "auth_ref": {
    "x3"
  },
  "auth_ref": []
},

```

```

"auth_ref": [
  "g0"
],
},
"dei_SecurityExchangeName": {
  "deiType": "SecurityExchangeNameItemType",
  "nsuri": "http://xbrl.sec.gov/dei/2023",
  "localName": "SecurityExchangeName",
  "presentation": {
    "http://BellevueLifeSciencesAcquisitionCorp.com/20241004/taxonomy/role/DocumentDocumentAndEntityInformation"
  },
  "lang": {
    "ns-uri": {
      "role": {
        "label": "Security Exchange Name",
        "terseLabel": "Security Exchange Name",
        "documentation": "Name of the Exchange on which a security is registered."
      }
    }
  },
  "auth_ref": [
    "g2"
  ]
},
"dei_SolicitingMaterial": {
  "deiType": "BooleanItemType",
  "nsuri": "http://xbrl.sec.gov/dei/2023",
  "localName": "SolicitingMaterial",
  "presentation": {
    "http://BellevueLifeSciencesAcquisitionCorp.com/20241004/taxonomy/role/DocumentDocumentAndEntityInformation"
  },
  "lang": {
    "ns-uri": {
      "role": {
        "label": "Soliciting Material",
        "terseLabel": "Soliciting Material",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 144-12 under the Exchange Act."
      }
    }
  },
  "auth_ref": [
    "g3"
  ]
},
"us-gaap_StatementClassOfStockAxis": {
  "deiType": "AxisItemType",
  "nsuri": "http://fasb.org/us-gaap/2023",
  "localName": "StatementClassOfStockAxis",
  "presentation": {
    "http://BellevueLifeSciencesAcquisitionCorp.com/20241004/taxonomy/role/DocumentDocumentAndEntityInformation"
  },
  "lang": {
    "ns-uri": {
      "role": {
        "label": "Class of Stock [Axis]",
        "terseLabel": "Class of Stock [Axis]"
      }
    }
  },
  "auth_ref": [
  ],
},
"dei_TradingSymbol": {
  "deiType": "TradingSymbolItemType",
  "nsuri": "http://xbrl.sec.gov/dei/2023",
  "localName": "TradingSymbol",
  "presentation": {
    "http://BellevueLifeSciencesAcquisitionCorp.com/20241004/taxonomy/role/DocumentDocumentAndEntityInformation"
  },
  "lang": {
    "ns-uri": {
      "role": {
        "label": "Trading Symbol",
        "terseLabel": "Trading Symbol",
        "documentation": "Trading symbol of an instrument as listed on an exchange."
      }
    }
  },
  "auth_ref": [
  ],
},
"disc_UnitsEachConsistingOfOneShareOfCommonStockOneRedeemableWarrantAndOneRight2Member": {
  "deiType": "DomainItemType",
  "nsuri": "http://BellevueLifeSciencesAcquisitionCorp.com/20241004",
  "localName": "UnitsEachConsistingOfOneShareOfCommonStockOneRedeemableWarrantAndOneRight2Member",
  "presentation": {
    "http://BellevueLifeSciencesAcquisitionCorp.com/20241004/taxonomy/role/DocumentDocumentAndEntityInformation"
  },
  "lang": {
    "ns-uri": {
      "role": {
        "label": "Units Each Consisting Of One Share Of Common Stock One Redeemable Warrant And One Right 2 [Member]",
        "terseLabel": "Units Each Consisting Of One Share Of Common Stock One Redeemable Warrant And One Right 2 [Member]"
      }
    }
  },
  "auth_ref": [
  ],
},
"dei_WrittenCommunications": {
  "deiType": "BooleanItemType",
  "nsuri": "http://xbrl.sec.gov/dei/2023",
  "localName": "WrittenCommunications",
  "presentation": {
    "http://BellevueLifeSciencesAcquisitionCorp.com/20241004/taxonomy/role/DocumentDocumentAndEntityInformation"
  },
  "lang": {
    "ns-uri": {
      "role": {
        "label": "Written Communications",
        "terseLabel": "Written Communications",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act."
      }
    }
  },
  "auth_ref": [
    "g6"
  ]
},
},
},
"std_ref": {
  "g0": {
    "role": "http://www.xbrl.org/2003/role/presentationRef",
    "Publisher": "SEC",
    "Name": "Exchange Act",
    "Number": "240",
    "Section": "12",
    "Subsection": "b"
  },
  "g1": {
    "role": "http://www.xbrl.org/2003/role/presentationRef",
    "Publisher": "SEC",
    "Name": "Exchange Act",
    "Number": "240",
    "Section": "12",
    "Subsection": "b-2"
  },
  "g2": {
    "role": "http://www.xbrl.org/2003/role/presentationRef",
    "Publisher": "SEC",
    "Name": "Exchange Act",
    "Number": "240",
    "Section": "12",
    "Subsection": "d1-1"
  },
  "g3": {
    "role": "http://www.xbrl.org/2003/role/presentationRef",
    "Publisher": "SEC",
    "Name": "Exchange Act",
    "Number": "240",
    "Section": "13a",
    "Subsection": "a-c"
  },
  "g4": {
    "role": "http://www.xbrl.org/2003/role/presentationRef",
    "Publisher": "SEC",
    "Name": "Exchange Act",
    "Number": "240",
    "Section": "14d",
    "Subsection": "2b"
  },
  "g5": {
    "role": "http://www.xbrl.org/2003/role/presentationRef",
    "Publisher": "SEC",
    "Name": "Exchange Act",
    "Section": "14d",
    "Number": "240",
    "Subsection": "12"
  },
  "g6": {
    "role": "http://www.xbrl.org/2003/role/presentationRef",
    "Publisher": "SEC",
    "Name": "Securities Act",
    "Number": "230",
    "Section": "425"
  },
  "g7": {
    "role": "http://www.xbrl.org/2003/role/presentationRef",
    "Publisher": "SEC",
    "Name": "Securities Act",
    "Number": "24",
    "Section": "8",
    "Subsection": "2"
  }
},
}
}

```